Evoke Pharma stock soars after QOL Medical acquisition announcement By Investing.com
Update: 2025-11-04
Description
Evoke Pharma, a company specializing in digestive treatments, has been acquired by QOL Medical, a biopharmaceutical company, in a deal that sent Evoke's stock soaring by 134%. The acquisition, valued at $11 per share, is nearly 140% higher than Evoke's stock price the day before. The deal is expected to close by the end of 2025, pending a few more steps. Evoke's unique product, GIMOTI, a nasal spray for diabetic gastroparesis, is a key driver of this move. QOL Medical plans to use its own funds to close the deal, and the merger will ensure that remaining shareholders receive $11 per share. This acquisition could significantly impact patients with rare or hard-to-treat digestive conditions.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
